4 questions about the FDA’s approach to generative AI

The medtech industry is awaiting FDA guidance on generative AI. The agency has sought feedback in advisory meetings and a discussion paper as the technology becomes more prevalent.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top